• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Nuvation Bio Inc.

    5/12/25 10:36:17 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    NUVATION BIO INC

    (Name of Issuer)


    CLASS A COMMON STOCK

    (Title of Class of Securities)


    67080N101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    67080N101


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    50,594,711.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    50,599,225.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    50,599,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    67080N101


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    50,599,225.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    50,599,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NUVATION BIO INC
    (b)Address of issuer's principal executive offices:

    357 TEHAMA STREET,FLOOR 3,SAN FRANCISCO,CA,USA,94103
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    CLASS A COMMON STOCK
    (e)CUSIP No.:

    67080N101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    50599225.00
    (b)Percent of class:

    15.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    50599225.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of NUVATION BIO INC. The interest of Fidelity Growth Company Commingled Pool, in the CLASS A COMMON STOCK of NUVATION BIO INC, amounted to 19388433.00 shares or 5.7% of the total outstanding CLASS A COMMON STOCK at 03/31/2025.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $NUVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    5/4/2022$14.00Buy
    H.C. Wainwright
    10/15/2021$16.00Buy
    BTIG Research
    More analyst ratings

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Blickenstaff Kim D

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      5/23/25 4:05:16 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Falberg Kathryn E

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      5/23/25 4:05:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vernon W Anthony

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      5/23/25 4:05:16 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

      Presentation will highlight the comparable efficacy and safety of taletrectinib across pivotal studies and different ethnicities and world regions The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional results from TRUST-I and TRUST-II, its pivotal Phase 2 clinical studies on the efficacy and safety of taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented at the upcomin

      5/21/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Participate in Upcoming Investor Conferences

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 3:00 p.m. ET in New York, NY 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 p.m. ET in New York, NY TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May

      5/12/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      11/12/24 10:32:11 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      10/18/24 4:15:55 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Nuvation Bio Inc.

      SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

      9/10/24 4:51:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    SEC Filings

    See more
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      5/23/25 2:21:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nuvation Bio Inc.

      SCHEDULE 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      5/12/25 10:36:17 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Nuvation Bio Inc.

      10-Q - Nuvation Bio Inc. (0001811063) (Filer)

      5/7/25 4:20:58 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Financials

    Live finance-specific insights

    See more
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

      Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently completing two pivotal studies for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC) Acquisition also adds safusidenib, a potentially best-in-class mutant IDH1 inhibitor currently being evaluated in a global Phase 2 study of patients with grades 2 and 3 IDH1-mutant glioma All-stock transaction preserves Nuvation Bio's robust cash balance and enables development of both new

      3/25/24 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PRESIDENT AND CEO Hung David bought $820,220 worth of shares (500,000 units at $1.64), increasing direct ownership by 0.86% to 58,781,054 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/8/25 9:30:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $166,985 worth of shares (100,000 units at $1.67) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/3/25 4:05:07 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $220,000 worth of shares (100,000 units at $2.20) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      10/10/24 4:33:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citizens JMP initiated coverage on Nuvation Bio with a new price target

      Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

      4/23/25 8:17:12 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously

      3/27/24 8:16:27 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by BTIG Research with a new price target

      BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00

      3/26/24 7:48:54 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

      Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

      10/7/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

      Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

      5/14/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

      Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

      3/28/24 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care